Immix Biopharma(IMMX)
$7.84-0.23 (-2.85%)
IMMX
Immix Biopharma financials statements
$7.84
At close:-0.23 (-2.85%)
Want to see IMMX full AI Analyst Report?
Immix Biopharma (IMMX) Ratios
220 Followers
Immix Biopharma Ratios
IMMX's free cash flow for Q3 2026 was $-12.43M. For the 2026 fiscal year, IMMX's free cash flow was decreased by $-121.24K and operating cash flow was $-12.31M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 10.01 | 2.33 | 5.32 | 11.70 | 90.01 |
| Quick Ratio | 10.01 | 2.33 | 5.32 | 11.70 | 90.01 |
| Cash Ratio | 9.29 | 2.04 | 4.70 | 10.55 | 87.33 |
| Solvency Ratio | -2.63 | -2.22 | -4.14 | -4.71 | -120.68 |
| Operating Cash Flow Ratio | -2.37 | -1.68 | -3.06 | -5.82 | -7.87 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | -31.79 |
| Net Current Asset Value | $ 90.19M | $ 10.50M | $ 16.07M | $ 13.15M | $ 17.98M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.05 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.01 | 0.08 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.01 | 0.08 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.12 | 1.73 | 1.21 | 1.13 | 1.01 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | -16553.48 | -105.29 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -16537.12 | -7.52 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.03 | 0.04 | 0.00 | 0.00 | 0.06 |
| Net Debt to EBITDA | 3.14 | 0.77 | 1.09 | 1.64 | 0.73 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.13% | 99.80% | 99.08% | 100.12% | 100.02% |
| EBT Per EBIT | 98.15% | 95.51% | 96.46% | 100.01% | 1803.08% |
| Return on Assets (ROA) | -28.08% | -94.18% | -77.42% | -55.20% | -134.04% |
| Return on Equity (ROE) | -31.39% | -163.11% | -94.03% | -62.54% | -135.54% |
| Return on Capital Employed (ROCE) | -31.62% | -159.00% | -99.62% | -60.28% | -7.52% |
| Return on Invested Capital (ROIC) | -31.58% | -158.28% | -99.62% | -60.28% | -7.49% |
| Return on Tangible Assets | -28.08% | -94.18% | -77.42% | -55.20% | -134.04% |
| Earnings Yield | -17.07% | -34.73% | -12.86% | -25.88% | -186.50% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.73 | -0.52 | -0.66 | -0.53 | -0.43 |
| Free Cash Flow Per Share | -0.75 | -0.56 | -0.66 | -0.53 | -0.43 |
| Dividend Paid and CapEx Coverage Ratio | -32.65 | -12.39 | -218.31 | 0.00 | -1981.68 |
| Capital Expenditure Coverage Ratio | -32.65 | -12.39 | -218.31 | 0.00 | -1981.68 |
| Operating Cash Flow Coverage Ratio | -22.30 | -13.58 | 0.00 | 0.00 | -31.79 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -14.30% | -25.35% | -9.52% | -23.30% | -12.16% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -5.88 | -2.89 | -7.78 | -3.86 | -0.54 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.84 | 4.70 | 7.31 | 2.42 | 0.73 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -6.99 | -3.95 | -10.50 | -4.29 | -8.22 |
| Price-to-Operating Cash Flow Ratio | -7.20 | -4.26 | -10.55 | -4.29 | -8.23 |
| Price-to-Earnings Growth (PEG) Ratio | -0.34 | 0.20 | -0.15 | 0.04 | -0.00 |
| Enterprise Value Multiple | -2.69 | -2.12 | -6.35 | -2.24 | 0.19 |
| Enterprise Value | 79.56M | 45.62M | 102.49M | 18.37M | -4.52M |
| EV to EBITDA | -2.69 | -2.12 | -6.35 | -2.24 | 0.19 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -3.23 | -2.89 | -8.97 | -2.48 | 2.84 |
| EV to Operating Cash Flow | -3.32 | -3.13 | -9.01 | -2.48 | 2.84 |
| Tangible Book Value Per Share | 2.85 | 0.47 | 0.93 | 0.95 | 4.90 |
| Shareholders’ Equity Per Share | 2.85 | 0.47 | 0.95 | 0.95 | 4.90 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.89 | -0.76 | -0.89 | -0.59 | -6.64 |
| Tax Burden | 1.00 | 1.00 | 0.99 | 1.00 | 1.00 |
| Interest Burden | 0.98 | 1.00 | 0.96 | 1.00 | 1.01 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.81 | 0.68 | 0.73 | 0.90 | 0.07 |
Currency in USD
